Sancilio Pharmaceuticals Company, Inc.
http://www.sancilio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sancilio Pharmaceuticals Company, Inc.
Pipeline Watch: Phase III Progress With Keytruda, Bempedoic Acid And Ubrogepant
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Patisiran, Etrolizumab, ALKS8700 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Starts With Rimegepant, ARQ087 And SGX942
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Emmaus Plans Modest Pricing In 4Q Rollout Of Sickle Cell Drug Endari
With an eye on a patient population mainly covered by Medicare and Medicaid, Emmaus Life Sciences CEO Yutaka Niihara says the company wants to ensure its pharmaceutical grade L-glutamine product is accessible in the US.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Sancilio & Company, Inc.
- Sancilio and Company, Inc.
- SCI
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice